The company
City Therapeutics, Inc.
CTY · Nasdaq
We hold no 150-day reading for CTY yet: it needs about 200 sessions of history. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- not in the set
- Weeks in an uptrend
- —
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $6.1M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 1
- Institutions holding
- 0
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
1 disclosed lines: House 1, Senate 0, executive 0; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Raúl M. Grijalva House: U.S. House ClerkAZ03 | sold | $1k–$15k | 15 Jan 2014filed 5 Feb 2014 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Robert NelsenDirector, 10% owner | bought | 170,000at $18.00 | 19 Oct 2026filed 19 Oct 2026 |
| Arch Venture Partners Xii, Llc10% owner | bought | 170,000at $18.00 | 19 Oct 2026filed 19 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|
News
No headline names it lately.
Everyone who traded it
Same industry
No other stock in its industry this week.
Government contracts
No federal award is tied to it.
From its SEC filings
No ratio computed from its SEC filings yet.
Analyst forecasts
No analyst forecasts yet.